To investigate the function of in the pathogenesis of gastric cancer (GC) and to explore the possible mechanisms involved in it. A quantitative real-time reverse transcription-PCR (RT-PCR) analysis was performed to evaluate miR-31 expression in GC cell lines. After transfecting GC cells with miR-31 precursors, Alamar blue and apoptosis assays were used to measure the respective proliferation and apoptosis rates. SGPP2 and Smad4 expression were determined by real-time RT-PCR and western blot assays after miR-31 transfection. Animal assay was used to further investigate miR-31 in the pathogenesis of GC. miR-31 was significantly reduced in GC tissues and GC cell lines, and that the reduced miR-31 was associated with distant metastasis and GC clinical pathological stages, miR-31 was lower at stages III/IV than that at stage II. SGPP2 and Smad4 were proven to be the direct target of miR-31. SGPP2 and Smad4 at mRNA and protein levels were negatively correlated with miR-31 in human GC tissues and cancer cell lines. Increased miR-31 significantly repressed SGPP2 and Smad4 at transcriptional and translational levels. Functional studies showed that increasing miR-31 inhibited GC cell proliferation, promoted apoptosis and attenuated cell migration, which were also linked to downregulation of STAT3. In vivo, miR-31 inhibited GC cell growth in tumor-bearing mice. This study has revealed miR-31 as a tumor suppressor and has identified SGPP2 and Smad4 as novel targets of miR-31, linking to STAT3 for regulating cancer cell proliferation, apoptosis and migration in GC. Therefore, miR-31 could be a useful biomarker for monitoring GC development and progression, and also could have a therapeutic potential by targeting SGPP2, Smad4 and STAT3 for GC therapy.
INTRODUCTION
Gastric cancer (GC) is the fourth most frequently occurring malignancy, exhibiting considerable geographic variation and ranks as the second leading cause of cancer-related deaths. 1 GC results from a combination of environmental factors and the accumulation of generalized and specific genetic alterations. 2 Although accumulating evidence shows that various genetic alterations cause tumorigenesis and progression of GC, 3 the molecular mechanisms underlying the pathogenesis of gastric carcinomas remain to be fully defined.
Metastasis is the most terrible aspects of cancer and has been studied for 4100 years. 4 In GC, the high mortality mainly attributes to delayed diagnosis because of the lack of specific symptoms in early stage. And metastasis is responsible for the GC-related mortality. 5 Migration and invasion of cancer cells are essential processes during cancer metastatic procession, which consists of a series of interrelated steps, including proliferation, detachment, circulation, transport, arrest in organs, adherence to vessel wall, establishment of a microenvironment and proliferation in distant organs. In GC, cells invasion into the surrounding tissue is a crucial early step. 6 However, the mechanisms of GC cells migration, invasion and metastasis have not been fully understood.
Recently, many epigenetic events are widely investigated in the cancer development. 6 Aberrant expression of miRNAs is reported in various types of cancers. 7, 8 The unregulated HER-2 activates a series of signaling pathways, prevents apoptosis and eventually leads to the cell proliferation disorders. Therefore, the HER-2 fusion gene is essential for the transformed cellular phenotype in GC. 9 In addition, the interaction between the progenitor cells expressing HER-2 and the environmental matrix may provide external signals that facilitate GC development. 10 The in-depth investigations into the GC pathogenesis in recent years have led to several targeted therapeutic protocols. However, the prognosis is still poor, with a long-term survival rate of only 30-40% for patients under 60 years old and 10% for patients above 60 years old. 11, 12 Therefore, understanding the fundamental mechanisms of GC and developing better treatment methods remain challenging. Recent studies have shown that the abnormal expression of miRNAs is associated with a variety of tumors as evidenced by their presence at fragile site in the genome functioning as oncogenes or tumor suppressor genes. 13 Recently, many researchers are looking into the potential use of miRNAs as prognostic tools other than diagnostic application, however, this specific marker needs to correlate closely with clinical outcomes and metastatic potential. Profiling of miRNAs seems to be advantageous over mRNAs in terms of cancer phenotypes differentiation. A current report suggested a prognostic signature for GC which consist of four risk miRNAs (miR-10b, miR-21, miR-223 and miR-338; with hazard ratio41) and three protective miRNAs (miR-30a-5p, miR-126 and let-7a; hazard ratioo 1), and was associated with clinical outcomes. 14 Another study showed that low expressions of miR-21 and miR-181b are associated with overall survival in patients treated with S-1 and doxifluridine. 15 Low expression of miR-125a-3p is correlated with tumor size, invasion, metastasis and advanced clinical stage, and an independent prognostic marker for GC. 16 On the other hand, the other strand of miR-125a, miR-125-5p also showed similar tumor suppressive effect in GC, and low expression was associated with poor prognosis. 17 Other study showed that HMGA2 expression was directly correlated with tumor invasiveness and prognosis, which is modulated by let-7 family. 18 A similar observation was also seen in pituitary adenomas, in which low expression of let-7 induced HGMA2 and related to tumor proliferation and invasion. 19 In GC, a growing body of evidence has implicated that miRNAs are involved in the processes of occurrence, progression and drug resistance of GC, and their associations with the specific hybrid gene could become a new therapeutic target. The present study was accordingly designed to detect cancer stem cell-related miRNAs, and explore their roles in GC development and progression to provide basis for the target therapy.
MATERIALS AND METHODS

Cell culture
The human GC cell lines MKN-1, MKN-7, AGS, SGC-7901 and BGC-823 and the normal gastric epithelium cell line GES-1 were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (Hyclone). Culture medium was Dulbecco modified Eagle medium and Ham F12 medium (DF12) containing 40% MCDB-201 medium complete with trace elements (MCDB) (Sigma, St Louis, MO, USA), 2% fetal calf serum (FCS; Gibco Life Technologies, Paisley, UK), 1 × insulin transferrin selenium (Gibco Life Technologies), 10 − 9 M dexamethasone (Sigma), 10 − 4 M ascorbic acid 2-phosphate (Sigma), 20 ng ml − 1 interleukin-6 (Sigma), 10 ng ml − 1 epidermal growth factor (Sigma), 10 ng ml − 1 platelet-derived growth factor BB (Sigma), 50 ng ml − 1 fetal liver tyrosine kinase 3 (Flt-3) ligand (Sigma), 30 ng ml − 1 bone morphogenetic protein-4 (Sigma), 100 U ml − 1 penicillin and 100 μg ml − 1 streptomycin (Gibco Life Technologies) at 37°C and a 5% CO 2 humidified atmosphere. Culture media were changed every 4 to 6 days.
Reverse transcription and real-time PCR to quantify mature miR-31
Total RNA was extracted with TRIzol (Invitrogen, Paisley, UK). For mature miRNA expression analysis, cDNA was synthesized with the Taqman MiRNA Reverse Transcription kit (Applied Biosystems, Paisley, UK) and 100 ng of total RNA (100 ng μl − 1 ), along with 1 μl of miR-31 (Applied Biosystems) specific primers that were supplied with the miRNA Taqman MicroRNA Assay, according to the manufacturer's instructions. Quantitative real-time PCR analyses were performed in triplicate on a 7900HT Real-Time PCR System (Applied Biosystems), and the data were normalized to RNU6B (Applied Biosystems) for each reaction. The thermal cycling profile used was as follows: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. Quantification was performed according to the standard ΔΔCt method.
Transfection of the miR-31 precursor
Cells were seeded 24 h prior to transfection into 24-well or 6-well plates or 6-cm dishes. Hsa-miR-31 (Applied Biosystems), or a miRNA mimic control (Applied Biosystems) was transfected with Lipofectamine 2000 (Invitrogen) at a final concentration of 50 nmol l − 1 . The sequences of the mature miR-31 used in this study were 5ʹ-GGUGCAGUGCUGCAUCUCUGGU-3ʹ and 5ʹ-UGAGAUGAAGCACUGUAGCUC-3ʹ. The cells were collected at 24 h (for RNA extraction), 48 h (for protein extraction) or 72 h (for apoptosis assays).
Cell viability assays
An Alamar blue assay was used to measure cell proliferation. This assay is based on the quantitative metabolic conversion of blue, nonfluorescent resazurin to pink, fluorescent resorufin by living cells. After 72 h of incubation, an Alamar blue (Invitrogen) stock solution was aseptically added to the wells to equal to 10% of the total incubation volume. The resazurin reduction in the cultures was determined after a 2-6-h incubation with Alamar blue by measuring the absorbances at 530 and 590-nm wavelengths on a Synergy HT Multi-Mode Microplate Reader (Bio-tek Instruments, Paisley, UK).
Apoptosis assay
Following maintenance in culture, the cells were collected and stained with phycoerythrin-conjugated Annexin V according to the manufacturer's instructions (BD Biosciences, Paisley, UK). The cells were then analyzed on a FACS Calibur flow cytometer (BD Biosciences). The cells were considered viable if double negative, early apoptotic if positive for Annexin V alone and necrotic or late apoptotic if double positive.
Western blot
Cells were collected, washed twice in PBS and lysed in lysis buffer (protease inhibitors were added immediately before use) for 30 min on ice. Lysate was centrifuged at 10 000 r.m.p. and the supernatants were collected and stored at − 70 in aliquots. All procedures were carried out on ice. Protein concentration was determined using BCA assay kit (Tianlai Biotech, Guangdong, China). miRNA real-time PCR Cells (1 × 10 2 -1 × 10 7 ) were collected, washed in PBS once and stored on ice; complete cell lysate was prepared by addition of 600 μl lysis binding buffer and vertex; 60 μl miRNA aomogenete addictive was added to the cell lysate and mixed thoroughly by inverting several times; sample was stored on ice for 10 min, followed by addition of equal volume (600 μl) of phenol:chloroform (1:1) solution; sample was mixed by inverting for 30-60 s, and then centrifuged at 12 000 g for 5 min; the supernatant was transferred to a new tube and the volume was estimated; 1/3 volume of 100% ethanol was added and mixed; the mixture was loaded to the column at room temperature and centrifuged at 10 000 g for 15 s; the flowthough was collected and the volume was then estimated; 2/3 volume of 00% ethanol was added and mixed; the mixture was loaded to column at room temperature and centrifuged at 10 000 g for 15 s; the flow-through was discarded; 700 μl miRNA wash solution was added to the column, followed by centrifugation at 10 000 g for 10 s; the flow-through was discarded; 500 μl miRNA wash solution was added to the column, followed by centrifugation at 10 000 g for 10 s; the flow-through was discarded; the column was transferred to a new tube and 100 μl preheated elution solution (95°) was added at room temperature; RNA was collected by centrifugation at 12 000 g for 30 s. SGPP2 forward: 5′-CCGGTG-GACCAAGTCCTTAC-3′; reverse: 5′-TCCATTGCAGGCAAACCAGA-3′; Smad4 forward: 5′-AGTCCCTGGATCACCGACAG-3′; reverse: 5′-GTTTCTTGCCTCTT-GGTTGCT-3′.
All the experiments were repeated at least three times.
Wound-healing assay
As reported previously, 20 
RESULTS
MiR-31 expression is reduced in GC cells
Using real-time PCR to quantify mature miR-31 in five human GC cell lines and a normal gastric epithelium cell line, we found that the miR-31 expression levels were markedly reduced in GC cells (P o 0.01; Figure 1a ). To determine the role of miR-31 in gastric epithelial cell malignant transformation, miR-31 expression levels were determined in human GC and their adjacent tissues. In comparison with the adjacent normal colon mucosa, 73% (34/46) of GC tissues shown reduced miR-31 expression, and only 27% (15/46) GCs exerted upregulated expression of miR-31, the difference was significant (Figure 1b , P o0.01). Western blot analysis indicated that SGPP2 and Smad4 protein expression was increased in the five human GC cell lines (Figure 1c ); this expression was inversely correlated with the miR-31 levels. More importantly, the reduced expression of miR-31 was also associated with colorectal cancer pathological stages -miR-31 levels were more downregulated at stages III/IV than those at stage II (Figure 1d , P o 0.0001).
MiR-31 decreases viability and increases apoptosis in GC cells
The reduced miR-31 expression in GC suggests that this miRNA could have anti-proliferative effects. To test this hypothesis, we evaluated the effects of transient transfection with miR-31 in MKN-7, AGS and SGC-7901 GC cell lines. The Alamar Blue assay, a redox assay similar to the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, showed significant decreases in GC cell viability following the transfection of miR-31 (P o 0.05; Figure 2a ). In addition, cell counts were significantly decreased after transfection with miR-31 (P o 0.05; Figure 2b ). Consistent with the results of the Alamar Blue assay, miR-31 showed a stronger inhibitory effect. An apoptosis assay after transfection with miR-31 indicated a marked increase in cell apoptosis. Cells transfected with miR-31 had a significantly higher apoptosis rate than those normal control (P o 0.05; Figure 2c and d) . Furthermore, miR-31 transfection were accompanied by increased levels of cleaved PARP, a product of apoptosis (Figure 2e ). SGPP2 and Smad4 were the targets of miR-31 Among the hundreds of targets, the two novel targets of miR-31, Sphingosine-1-phosphate phosphatase 2 (SGPP2) and Smad4, were chosen for further studies. SGPP12 is a catalyze of Sphingosine-1-phosphate (S1P), the later is a bioactive sphingolipid metabolite that regulates diverse biologic processes, 11, 14 and recent report showed that SIP is linked to signal transducer and activator of transcription 3 (STAT3) activation and the development of colitis-associated colorectal cancer. 15 But the biological role of SGPP2 on carcinogenesis is not clear. Smad4 is a member of Smad family and is associated with cell growth and proliferation through transforming growth factor (TGF) signaling pathway. 15, 17 Genomic alignment showed that 3′-UTR of SGPP2 and Smad4 have one or two miR-31 binding sites (Figure 3a ). To determine whether miR-31 could repress SGPP2 and Smad4 expression by targeting its binding site at 3′-UTR in SGPP2 and Smad4, the PCR products containing full length of 3′-UTR with intact target site of miR-31 recognition sequences were inserted into the luciferase reporter vector. The plasmids were transfected into SGC-7901 cells that had been transfected with control miRNA mimics or miR-31 mimics, and the luciferase reporter activities were measured. As shown in Figure 3b , SGPP2 reporter activities were reduced about 65% and both of the Smad4 reporter activities were reduced about 90%, respectively. These finding confirmed that SGPP2 and Smad4 were the targets of miR-31. The repression of SGPP2 and Smad4 expression by miR-31 were determined by qRT-PCR and immunoblotting. As shown in Figure 3c , SGPP2 and Smad4 mRNA and protein levels were repressed by miR-31 in SGC-7901 cells, respectively, consistent with the repression on their reporter luciferase activities. SGPP2 and Smad4 protein levels were also downregulated by miR-31 on both SGC-7901 and AGS GC cells (Figure 3d ). SGPP2 and Smad4 were inversely correlated with miR-31 in GC As SGPP2 and Smad4 were likely the targets of miR-31, we then determined the expression levels of SGPP2 and Smad4 in human GCs and cancer cell lines. As shown in Figure 4a , SGPP2 mRNA (Figure 4a ). The expression of SGPP2 and Smad4 were then evaluated in human GCs by immunohistochemical staining. Compared with the adjacent normal colon mucosa, both SGPP2 and Smad4 expression were much higher at gastric adenocarcinomas (Figure 4b ).
MiR-31 inhibited cell proliferation, enhanced apoptosis and attenuated cancer cell migration
To determine miR-31 tumor suppressing functions, miR-27a precursor were transfected into the gastric cancer cell lines, and the effects on cell proliferation, apoptosis and migration were analyzed. As shown in Figure 5a and b, increasing miR-31 significantly inhibited cancer cell proliferations after 48 and 72 h at MKN-1, MKN-7, AGS, SGC-7901 and BGC-823 cells, although the effects at 24 h post transfection were not changed. In addition, increasing miR-31 significantly enhanced cancer cell apoptosis (45% at miR-27a groups versus 15% at vector control group, Po 0.01). The examples of apoptosis changes were shown at Figure 5c . Moreover, increased miR-31 significantly attenuated SGC-7901 cancer cell migration at 24 and 48 h after transfection, assayed by wound healing (Figure 5d ). As miR-31 was reduced in human GCs, we determined whether p-STAT3 was increased in GCs. P-STAT was indeed increased in GCs (Figure 5e ).
MiR-31 inhibited cancer growth in mice
To determine miR-31 tumor suppressing effects in vivo, we transplanted murine GC cells SGC-7901 into wild-type C57Bl/6 mice and injected a mixture of miR-31 precursor and Lipofectamine 2000 into the tumors when the tumors were palmable at day 21 post inoculation. Compared with vector control, miR-31 treatment significantly inhibited cancer cell growth in mice, in terms of significant reduction of tumor sizes and weight (Figure 6a and b) . qRT-PCR showed that miR-31 level was still at a higher level in the tumors isolated from mouse xenografts (Figure 6c ).
DISCUSSION
GC, one of the most common malignancies worldwide, is the second most frequent cause of cancer death. 14, 15 The high mortality of GC is a consequence of late stage of diagnosis, the 5-year survival rate for advanced stages is extremely poor and around 5-15%. 16, 17 Although diagnosis and treatment of GC have improved, the survival rate has not increased substantially in couple of years. Therefore, an improved understanding of the molecular pathways involved in the progression of GC will be helpful in improving prevention, diagnosis and therapy of this disease. 18, 19, [21] [22] [23] In the present study, the expression levels of miR-31 was found to be downregulated in GC. This finding is consistent with reports from other research groups. 23, 24 In a recent report, the authors used real-time RT-PCR and chip assays to analyze 70 paired samples of GCs and benign tissues. 24 The authors found that miR-31 was among the most strongly downregulated miRNAs in GCs, compared with benign tissues. The miR-143 expression level was associated with GC progression and was more significantly reduced in stage IV cancers, compared with stage I and II cancers. Consistent with our observations, a study 23 also indicated that miR-31 was downregulated in GC cell lines and that transfection with miR-31 inhibited the GC cell viability by targeting ERK5 and AKT. However, the function of miR-31 has never been investigated in GC.
Our functional analysis of miR-31 expression in GC cell lines indicated tumor suppressor functions for miR-31. Our data revealed that the restoration of miR-31 expression suppressed cell proliferation and promoted apoptosis in GC cells. Further analysis demonstrated that only miR-31 directly binds to SGPP2 miR-31 inhibits gastric carcinogenesis and Smad4 mRNA. The luciferase reporter assay revealed that SGPP2 and Smad4 contain a binding site for miR-31. The mechanistic studies further showed that miR-31-mediated tumor suppressor could be through targeting SGPP2, Smad4 and STAT3. Previous studies have demonstrated that Apc mutation and Wnt/ b-catenin signaling activation, and chronic inflammation in colon, are the two major causes for colorectal cancer formation. 20, [25] [26] [27] [28] The studies from us have shown that genetic deletion of the Muc2 gene is sufficient to cause gastric colitis and inflammation at early stage, and leads to cancer formation at late stage. 9, 23, 29, 30 The malignant transformation is linked to the activation of inflammatory signaling and upregulation of cytokines. 23, 31 And the chronic inflammation facilitated Apc-mutation caused gastrointestinal tumor formation in the Apc/Muc2 double gene knockout mouse model of colorectal cancer. 23 In fact, other studies have demonstrated that the transcription factor STAT3 also plays a critical role in inflammation-associated GC formation. 30, 31 During the transition of chronic gastric inflammation to colitisassociated cancer, STAT3 could be persistently activated by sphingosine-1-phosphate (S1P) produced by upregulation of sphingosine kinase 1 (SphK1), which was linked to production of the multifunctional NF-kB-regulated cytokine interleukin-6, and consequently upregulating of the S1P receptor, S1PR1. 31 While, the balance of S1P levels are regulated by sphingosine-1phosphate phosphatase 1 (SGPP1). 32 Using comprehensive approaches, including qRT-PCR, immunoblotting and in situ immunohistochemical staining, we showed that the expression of SGPP2 at mRNA and protein levels were upregulated in GCs and GC cell lines, which were inversely correlated with the expression of miR-31. Both dual luciferase assay and increasing expression of miR-31 further showed the inhibitory effects of miR-31 on SGPP2. Thus, this is the first to reveal that SGPP2 is a potent direct target of miR-31, although the evidence of direction regulatory interaction is needed for further investigation. Limited studies have demonstrated that SGPP2 catalyzes the degradation of S1P via salvage and recycling of sphingosine into long-chain ceramides, and that aberrant expression of SGPP2 is associated with idiopathic pulmonary fibrosis, and pulmonary fibrosis. 31 However, the biological functions for SGPP2 in carcinogenesis are largely unknown and worthy further elucidative.
Smad4 is a member of the Smad family and is a key element in TGF signaling. Therefore, accompanying actions of TGF in different circumstances, for example, in regulating development and differentiation in physiological cell process, and in facilitating cell growth and migration and angiogenesis in cancers, Smad4 exerts dual functions as tumor suppressor or oncogene. 30, 33, 34 In the current study, we found that, similar as SGPP2 and Samd4 expression at mRNA and protein levels was upregulated in GCs and cell lines, exhibiting oncogenic phenotypes; moreover, Smad4 was repressed at transcriptional and translational levels by miR-31, suggesting the direct target of miR-31, a novel finding that has not been reported previously. A few recent studies have reported that Smad4, similar as Smad2 and Smad3, is mutant in cancers, 35 but Smad4 has differential roles from Smad2 and Samd3 in TGF signaling. 30 Previous studies have also shown therapeutic role of Smad4, that blocking Smad4 could suppress TGF-induced miR-31 inhibits gastric carcinogenesis tumorigenesis, epithelial mesenchymal transition (EMT), cell motility, and invasion, 36 indicating that targeting miR-31/Smad4 could have a great impact on developing a novel strategy for GC therapy. The new signal pathway of miR-31-Smad4-TGF could also contribute to the inhibitory role of miR-31 on cancer cell migration, invasion and metastasis, detailed mechanism is under investigation.
In summary, we have demonstrated that miR-31 is frequently downregulated in GC, 37 and the reduced miR-31 is correlated with cancer distant metastasis and histopathological stages, and thus, miR-31 acts as a tumor suppressor. Both in vivo and in vitro studies have identified SGPP2 and Smad4 as two novel targets of miR-31, which is linked to STAT3 to regulate cancer cell proliferation, apoptosis and migration. Therefore, miR-31 could be a useful biomarker for GC development and progression, and also could have a therapeutic potential targeting SGPP2, Smad4 and STAT3 for colorectal cancer therapy. 
